S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The 3-Stock Retirement Blueprint (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
3rd Massive Dollar Upheaval Has Started (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The 3-Stock Retirement Blueprint (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
3rd Massive Dollar Upheaval Has Started (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The 3-Stock Retirement Blueprint (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
3rd Massive Dollar Upheaval Has Started (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The 3-Stock Retirement Blueprint (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
3rd Massive Dollar Upheaval Has Started (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
NASDAQ:PODD

Insulet - PODD Stock Forecast, Price & News

$268.61
-2.03 (-0.75%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$264.40
$271.67
50-Day Range
$198.33
$270.70
52-Week Range
$181.00
$324.81
Volume
326,395 shs
Average Volume
564,032 shs
Market Capitalization
$18.64 billion
P/E Ratio
537.22
Dividend Yield
N/A
Price Target
$292.33

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
8.8% Upside
$292.33 Price Target
Short Interest
Healthy
3.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.34mentions of Insulet in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$4.64 M Sold Last Quarter
Proj. Earnings Growth
68.97%
From $0.87 to $1.47 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

581st out of 1,124 stocks

Surgical & Medical Instruments Industry

53rd out of 113 stocks

PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PODD. Piper Sandler upped their target price on Insulet from $230.00 to $235.00 and gave the stock a "neutral" rating in a research report on Friday, August 5th. BTIG Research increased their price objective on shares of Insulet to $285.00 in a research report on Tuesday, August 9th. Raymond James boosted their target price on shares of Insulet from $262.00 to $280.00 in a research report on Friday, August 5th. Citigroup raised their price target on shares of Insulet to $260.00 in a report on Tuesday, August 9th. Finally, Robert W. Baird boosted their price objective on shares of Insulet from $245.00 to $300.00 and gave the stock an "outperform" rating in a report on Friday, August 5th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $295.23.

Insulet Stock Down 0.8 %

Insulet stock traded down $2.03 during midday trading on Tuesday, hitting $268.61. The stock had a trading volume of 326,395 shares, compared to its average volume of 564,032. The business has a fifty day moving average price of $233.93 and a 200 day moving average price of $238.18. Insulet has a 12 month low of $181.00 and a 12 month high of $324.81. The stock has a market cap of $18.64 billion, a P/E ratio of 537.22 and a beta of 0.73. The company has a current ratio of 4.69, a quick ratio of 3.54 and a debt-to-equity ratio of 3.28.

Insulet (NASDAQ:PODD - Get Rating) last issued its earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.72). Insulet had a return on equity of 13.83% and a net margin of 2.94%. The firm had revenue of $299.40 million during the quarter, compared to analyst estimates of $290.87 million. During the same quarter in the previous year, the business posted $0.10 EPS. Insulet's revenue was up 13.8% compared to the same quarter last year. Research analysts predict that Insulet will post 0.87 EPS for the current year.

Insiders Place Their Bets

In other news, COO Charles Alpuche sold 6,000 shares of Insulet stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $215.32, for a total value of $1,291,920.00. Following the completion of the transaction, the chief operating officer now directly owns 43,899 shares of the company's stock, valued at approximately $9,452,332.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, COO Charles Alpuche sold 6,000 shares of the stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $215.32, for a total transaction of $1,291,920.00. Following the sale, the chief operating officer now directly owns 43,899 shares in the company, valued at approximately $9,452,332.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shacey Petrovic sold 15,000 shares of the business's stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $222.90, for a total value of $3,343,500.00. Following the transaction, the director now owns 13,695 shares of the company's stock, valued at approximately $3,052,615.50. The disclosure for this sale can be found here. 0.90% of the stock is owned by corporate insiders.

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Insulet (NASDAQ:PODD) PT Raised to $290.00
Insulet (NASDAQ:PODD) Price Target Raised to $235.00
Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates
Insulet (PODD) to Release Quarterly Earnings on Thursday
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Company Calendar

Last Earnings
8/04/2022
Today
8/17/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,300
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$292.33
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$235.00
Forecasted Upside/Downside
+8.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$16.80 million
Pretax Margin
3.55%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.07 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
68,779,000
Market Cap
$18.64 billion
Optionable
Optionable
Beta
0.73

Social Links















PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price forecast for 2022?

12 brokers have issued 1 year price targets for Insulet's stock. Their PODD share price forecasts range from $235.00 to $350.00. On average, they expect the company's share price to reach $292.33 in the next year. This suggests a possible upside of 8.8% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2022?

Insulet's stock was trading at $266.07 on January 1st, 2022. Since then, PODD stock has increased by 1.0% and is now trading at $268.61.
View the best growth stocks for 2022 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PODD earnings forecast
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, August, 4th. The medical instruments supplier reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by $0.72. The medical instruments supplier earned $299.40 million during the quarter, compared to the consensus estimate of $290.87 million. Insulet had a trailing twelve-month return on equity of 13.83% and a net margin of 2.94%. The firm's revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 earnings per share.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its third quarter 2022 earnings guidance on Thursday, August, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $322.45 million-$330.72 million, compared to the consensus revenue estimate of $309.85 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (5.00%), Clearbridge Investments LLC (2.40%), D1 Capital Partners L.P. (1.78%), Primecap Management Co. CA (1.71%), Echo Street Capital Management LLC (1.16%) and Allspring Global Investments Holdings LLC (0.82%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $268.61.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $18.64 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.50 on an earnings per share basis.

How many employees does Insulet have?

The company employs 2,300 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.